Kaposi's sarcoma secondary prevention: Difference between revisions
No edit summary |
Hudakarman (talk | contribs) |
||
| (7 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Kaposi's sarcoma}} | {{Kaposi's sarcoma}} | ||
{{CMG}} {{shyam}} | |||
==Overview== | |||
[[Secondary Prevention|Secondary prevention]] of Kaposi's sarcoma involves [[Antiretroviral therapy|anti-retroviral therapy]] which can improve the [[CD4]] [[T cell]] count. | |||
==Secondary Prevention== | |||
[[Secondary prevention]] of Kaposi's sarcoma involves [[Antiretroviral therapy|anti-retroviral therapy]] which can improve the [[CD4]] [[T cell]] count. Lower [[CD4]] [[T cell]] counts (below 150 cells per microliter) are associated with worse [[prognosis]] and will result in worsening [[complications]]. Highly-active [[Antiretroviral therapy|anti-retroviral therapy]] is important for [[prevention]] of worsening [[disease]] in [[patients]] who have Kaposi's sarcoma.<ref name="pmid18665172">{{cite journal| author=Franceschi S, Maso LD, Rickenbach M, Polesel J, Hirschel B, Cavassini M et al.| title=Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. | journal=Br J Cancer | year= 2008 | volume= 99 | issue= 5 | pages= 800-4 | pmid=18665172 | doi=10.1038/sj.bjc.6604520 | pmc=2528138 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18665172 }} </ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | |||
{{WH}} | |||
{{WS}} | |||
[[Category:Needs content]] | [[Category:Needs content]] | ||
| Line 11: | Line 22: | ||
[[Category:HIV/AIDS]] | [[Category:HIV/AIDS]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Vascular medicine]] | |||
[[Category:Surgery]] | |||
Latest revision as of 17:20, 9 October 2019
|
Kaposi's sarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Kaposi's sarcoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Kaposi's sarcoma secondary prevention |
|
Risk calculators and risk factors for Kaposi's sarcoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Overview
Secondary prevention of Kaposi's sarcoma involves anti-retroviral therapy which can improve the CD4 T cell count.
Secondary Prevention
Secondary prevention of Kaposi's sarcoma involves anti-retroviral therapy which can improve the CD4 T cell count. Lower CD4 T cell counts (below 150 cells per microliter) are associated with worse prognosis and will result in worsening complications. Highly-active anti-retroviral therapy is important for prevention of worsening disease in patients who have Kaposi's sarcoma.[1]
References
- ↑ Franceschi S, Maso LD, Rickenbach M, Polesel J, Hirschel B, Cavassini M; et al. (2008). "Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy". Br J Cancer. 99 (5): 800–4. doi:10.1038/sj.bjc.6604520. PMC 2528138. PMID 18665172.